A Neoadjuvant Study of Abemaciclib (LY2835219) in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast Cancer

Clinical trial NCT02441946 · COMPLETED

Trial details

NCT number: NCT02441946
Sponsor: Eli Lilly and Company
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Breast Cancer Hormone Receptor Positive Tumor Early-Stage Breast Carcinoma

Start date: 2015-08-01
Primary completion: 2016-08-16
Enrollment: 224

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.